Targeting STAT3 to prevent non-small cell lung cancer (nsclc) in patients with chronic obstructive pulmonary disease (copd)
Ended Awarded Last action
- Contract number
- 75N91022F00002
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,097,981
Award facts
- Opportunity
-
- TORFP2022E09 Solicitation number
- Contract value 100% obligated
- $1,097,981.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,097,981 |
About this award
The National Cancer Institute (NCI) awarded a $1.1M firm fixed-price delivery order to The University of Texas MD Anderson Cancer Center for the "Targeting STAT3 to Prevent Non-Small Cell Lung Cancer (NSCLC) in Patients with Chronic Obstructive Pulmonary Disease" research project. The award was issued on September 15, 2022, with an ultimate completion date of June 14, 2026, and will be performed in Houston, Texas. This delivery order is issued under the NCI's larger PREVENT Cancer Preclinical Drug Development Program, a $150M indefinite delivery contract that evaluates potential cancer preventive agents through preclinical efficacy testing and biomarker evaluation. The work has no set-aside designation, reflecting MD Anderson's competitive standing as a premier academic cancer research institution.
MD Anderson will conduct preclinical research to investigate STAT3 as a therapeutic target for preventing NSCLC in patients with COPD, contributing to the NCI's cancer prevention research agenda. As a National Cancer Institute-designated Comprehensive Cancer Center and component of the University of Texas System, MD Anderson brings substantial expertise in translational cancer research, multidisciplinary clinical teams, and complex preclinical drug development programs. The delivery order structure enables efficient allocation of resources while maintaining accountability under the parent IDIQ vehicle, which remains active through January 24, 2029.
Quick answers
Who was awarded contract 75N91022F00002?
75N91022F00002 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 15, 2022.
How much is contract 75N91022F00002 worth?
The government has obligated $1,097,981 on 75N91022F00002.
Is contract 75N91022F00002 an order under another contract?
Yes. 75N91022F00002 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91022F00002 competed?
The extent of competition for 75N91022F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award